Fudan University Shanghai Cancer Centerpudong

Shanghai, Shanghai Municipality 201321

7 studies enrolling now · 7 studies all time

What they study most

Advanced Breast Cancer, Advanced Solid Tumor, Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancer

Studies at this site

• A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors — Recruiting now
• A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors — Recruiting now
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors — Recruiting now
• An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors — Recruiting now
• An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors — Recruiting now
• A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors — Recruiting now
• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer — Recruiting now